Loading...
Expert Guide to the Pharma Industry & it's biggest challenges
34
Registered
Registration
Registration is now closed (this event already took place).
Details
Join us in welcoming Jesús Hernández, MD, Ph.D, a pharma/biotech consultant with over 30 years experience in leadership positions in the pharma & biotech sectors. His extensive experience includes leadership positions at Eli Lilly (former Vice-president for Medical Affairs, Europe), Center for Applied Medical Research (CIMA), University of Navarra (CEO), and Digna Biotech (CEO).
He holds an MD and a Ph.D in Medicine and is a specialist in Infectious Diseases. He has also taken senior executive programs at IESE Business School, Harvard Business School, Harvard Medical School, INSEAD and London Business School, and is an Assoc. Prof. at the University of Navarra.
During his talk he will provide an introductory overview of the sector and cover the trends and challenges—both present and future—of the pharmaceutical industry, followed by Q&A.
Where
MARIA DE MOLINA, 31
MM 201
Calle de María de Molina, 31, 28006 Madrid, Spain
Speakers
Jésus Hernandez
MD, Ph.D
Eli Lilly, CIMA - Center for applied Medical Research, DIGNA Biotech
https://www.linkedin.com/in/jesusmhernandez/
Jesús M. Hernández has 30 years of experience in leadership positions in pharma & biotech, and in academic drug discovery and tech transfer.
He spent 20 years in Eli Lilly and Company, where he started his career as clinical research physician moving soon to the management ladder, and holding different executive positions in the European Management team as Executive Director for Clinical Research and Regulatory Affairs and eventually as Vice-president for Medical Affairs, Europe. During that time, he had the opportunity to build high-performance teams of skillful medics, operations and regulatory experts, having an active participation in the development, EMA’s registration and commercialization of Zyprexa, Cymbalta, Alimta, Strattera, Gemzar, Cialis, Humalog, Byetta, Forsteo, Efient, ReoPro and Xigris. He also had a significant contribution in the transformation of business models, especially around patient outcomes research and integrated patient and prescriber approaches.